Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01139450 · ClinicalTrials.gov registry record · Phase 3
Study of 0417 Ointment in the Treatment of Atopic Dermatitis
A Phase 3 study, sponsored by Fougera Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 899
- Enrollment target
NCT01139450 is a Phase 3 study that has completed, run by Fougera Pharmaceuticals. The registered enrollment target is 899 participants.
The verdict
NCT01139450, a Phase 3 study, has completed, sponsored by Fougera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 899 participants
- Enrollment target
Study Summary
The aim of this trial is to assess the efficacy of 0417 Ointment in the Treatment of Atopic Dermatitis. Treatment medication will be administered as follows: Apply a thin layer of ointment to affected skin areas twice daily and rub in gently and completely. Study medication will be applied twice a day, approximately 12 hours apart, for approximately 4 weeks.
Interventions
- DRUG 0417
- DRUG Vehicle of 0417 test product
- DRUG Tacrolimus Ointment 0.03%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 899 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01139450
The ClinicalTrials.gov registry entry for NCT01139450 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 899 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fougera Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 0417 is the first listed.
NCT01139450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01139450 about?
NCT01139450 is a clinical study titled "Study of 0417 Ointment in the Treatment of Atopic Dermatitis". The aim of this trial is to assess the efficacy of 0417 Ointment in the Treatment of Atopic Dermatitis. Treatment medication will be administered as follows: Apply a thin layer of ointment to affected skin areas twice daily and rub in gently and completely. Study medication will be applied twice a ...
What is the current status of trial NCT01139450?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 899 participants. The study started on 2008-01. Estimated completion is 2009-08.
What interventions are being tested in trial NCT01139450?
The interventions under investigation include: 0417 (DRUG), Vehicle of 0417 test product (DRUG), Tacrolimus Ointment 0.03% (DRUG).
Who is sponsoring clinical trial NCT01139450?
This trial is sponsored by Fougera Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.